Abstract
Hidradenitis suppurativa is one of the most distressing dermatological conditions and has a significant negative impact on patients' quality of life. However, the exact pathogenic mechanisms remain incompletely understood and—therefore—efficient therapies are still lacking. The current manuscript focuses on new findings on its pathogenic mechanisms and aims to provide practical therapy recommendations.
Introduction
Hidradenitis suppurativa (HS) is a chronic skin disorder, which profoundly decrease quality of life because of emotional, physical and psychologic consequences (–). This recurrent inflammatory skin condition with an estimated prevalence of 1–4% is more frequent in women (, , , ). Most frequently, the age of onset is between 20 and 40 years of life, although postmenopausal women and prepubertal children with new-onset HS have been reported (, , , ). The clinical manifestations range from inflamed nodules and abscesses to draining sinus tracts and formation of scars (, , ). The pain, drainage, malodor, and disfigurement associated with HS all contribute to the remarkable psychosocial impact of the disease with negative effects on the patients' quality of life that cannot be overestimated (, , ). In fact, HS is associated with an increased risk of completed suicide, an increased risk of adverse cardiovascular outcomes and increased all-cause mortality independent of measured confounders (, ). Unfortunately, the exact pathogenesis of HS remains unclear. Despite the existence of multiple therapeutic approaches and combinational treatments, effective management of moderate to severe HS remains elusive in many cases. In this manuscript, we summarize the current knowledge about pathophysiology and treatment of HS.
Pathogenesis
Mechanism
The precise pathogenesis of HS remains still unclear. This chronic skin disorder might be caused by genetic, endocrine, environmental, and microbiological factors (). The primary event in disease development is thought to be follicular occlusion, based on histopathological observations in very early lesions (, ). Follicular occlusion is likely due to infundibular keratosis and hyperplasia of the follicular epithelium, which leads to accumulation of cellular debris and formation of cysts (, –). The hair follicle eventually ruptures, followed by release of follicular contents to the dermis, which induces a significant expression of inflammatory mediators and recruitment of inflammatory cells. The end results are abscess formation, painful inflammation and sinus tract formation and scarring, in later stages (, –).
Genetics
Two main observations point to a genetic background of HS. First, approximately one third of HS patients have at least one family member also suffering from HS, suggesting an inheritable genetic predisposition (). Second, families with several mutations or changes in genes of the gamma-secretase family (including nicastrin (NCSTN), presenilin 1 (PSEN1), presenilin enhancer 2 (PSENEN) gene mutation) show an autosomal dominant inheritance of HS, indicating a pathogenic role of these genes in HS (–). The resulting alteration in γ-secretase function might result in HS by affecting downstream Notch signaling in the skin ().
However, these patients show a severe disease phenotype not entirely typical of “sporadic” HS, raising questions as to what degree this genetic background is representative for all cases of HS. Nevertheless, taken together current evidence strongly supports a genetic predisposition for HS development.
Inflammatory Pathways in Hidradenitis Suppurativa
The excessive inflammatory response seen in lesional skin of HS is thought to be triggered by a combination of genetic, anatomical, immunological, and environmental factors (, ). Increased activity of dendritic cells and T cells cause keratinocyte hyperplasia via the actions of IL-23 and IL-12 and a Th17 immune response (–). As HS progresses, increased levels of interleukin (IL)-1, tumor necrosis factor (TNF), IL-17, caspase-1, S100A8, S100A9, and IL-10 appear in the tissue together with a recruitment of neutrophils, mast cells and monocytes (, , , –). Recent evidence further points to autoinflammatory mechanism in HS. HS skin shows increased formation of neutrophil extracellular traps (NET). Intriguingly, immune responses to neutrophil and NET-related antigens have been linked to enhanced immune dysregulation and inflammation (). In combination with the strong type I IFN signature in HS skin, these findings suggest a key involvement of the innate immune response in the pathogenesis of HS (). As healing from the remarkable inflamation progresses, tunneling and scarring of the tissue occur (, , ). The development of sinus tracts and scarring is associated with matrix metalloproteinase-2 (MMP-2), transforming growth factor beta (TGF-ß) and (Intercellular adhesion molecule-1 (ICAM-1), with possible augmentation of TGF-ß and ICAM-1 signaling via specific components of the microbiome (, ).
Bacteria
Bacterial involvement in HS pathogenesis remains highly debated (, ). A number of studies have shown that cultures of HS lesions are predominately sterile or contain only commensal skin flora (, ). As a result, primary infection is viewed as an unlikely cause of HS (, ). In addition, the lack of strong therapeutic effect of antibiotic treatment further argues against a primary infectious cause (). However, it is still possible that microbial “dysbiosis” and an altered skin microbiome are important factors contributing to HS pathogenesis. In fact, the cutaneous microbiome in patients with HS is substantially different from that of normal donors. A variety of partly overrepresented, partly unique species have been isolated from HS lesions and linked to various features of the disease (, ). Yet, their pathogenetic contribution has remained elusive, in large part because of the technical and experimental difficulties of investigating their causal role in humans (, ). Furthermore, the microanatomical intricacies of HS skin with its fistulas and sinus tracts represent an important basis for biofilm formation, bacterial colonization, and secondary infection, which contribute to disease exacerbations, suppuration and extension of lesions (, ). Although the role of bacterial biofilm in HS is highly debated, the association between biofilm and the number of regulatory T cells (TREG) in a recent study supports the concept of dysbiosis as a factor in the preclinical HS lesions (). In summary, microbial colonization and infection are likely pathogenic contributors to HS, but it is still unclear if the colonization of bacteria is a primary or secondary event in the evolution of HS (). Since the follicular infundibulum is populated by a broad microbiome, deficiencies in the follicular skin immune system might cause microbial overgrowth. However, another theories suggest that an overactive immune system might contribute to a remarkable inflammatory response to harmless, normal flora ().
Other Associated Factors
Mechanical stress (), metabolic syndrome (, , ), diet (), smoking (, ), and hormonal factors () have been reported in previous studies to contribute to the development or exacerbation of HS. While the epidemiological evidence for this is undisputed, at least for some factors such as smoking and obesity, the mechanism by which these factors contribute to HS pathogenesis remain far from clear. Smoking, for instance, is one of the best-documented behavioral risk factors for HS, but the mechanisms by which it triggers HS is poorly understood. There are thousands of chemicals in tobacco smoke, which have the potential to activate keratinocytes, fibroblasts, and immune cells. Mechanistically, these substances may trigger skin cells via two types of receptors: aryl hydrocarbon receptors and nicotinic acetylcholine receptors (, , ). In keratinocytes, activation of these receptors can lead to infundibular epithelial hyperplasia, acanthosis and excessive cornification (, ). Furthermore, tobacco smoke can induce expression of proinflammatory cytokines such as TNF-a, IL-8, IL-1 α, and IL-1β leading to neutrophil chemotaxis, altered function of TREG, as well as activation of Th17 pathways (, , –). Other important risk factors for HS, obesity and diabetes, can also result in overproduction of TNF-α, IL-1β, and IL-6 through activated macrophages in adipose tissue (, –). In addition, obesity can worsen HS through increased skin-clothing and skin-skin friction, as mechanical stress can increase follicular occlusion and rupture (, ).
Hormones are also thought to be involved in HS pathogenesis. This is primarily based on a number of clinical observations and promising effects of antiandrogen treatments. For instance, some female HS patients observe worsening of disease in conjunction with menstruation or after starting hormonal contraception with androgen effects (e.g., progesterone-containing drugs) (, ). Hormones can induce occlusion and plugging of the follicle and increase production and composition of sebum, thereby contributing to the vicious cycle of HS skin inflammation (, ).
Suggested Therapy Approach Based on the Current Knowledge
There is no single efficient therapy for the skin disorder. As a result, clinicians typically should choose from different treatment modalities and often have to combine them to achieve disease control. The choice of treatment depends on the distribution and overall severity of disease, the anatomic location and inflammatory activity of the lesions, the patient's comorbidities, as well as treatment cost and availability (, , , ). In order to assess the severity and extent of hidradenitis suppurativa various scoring systems are in common use: hurley stages, sartorius hidradenitis suppurativa score, hidradenitis suppurativa physician global assessment (HS-PGA) and hidradenitis suppurativa clinical response (HiSCR) (–59).
HS management is often complex. The standard of care management requires an individualized approach in a multifaceted approach, ranging from self-management (e.g., avoidance of skin trauma, pain management, smoking cessation, weight loss and hygiene practices) to local therapies, systemic antibiotics, and a wide range of immunomodulating agents, as well as surgical interventions such as excisional and laser surgeries (, , , , 60). Additionally, the diagnosis and management of medical comorbidities and referral to psychiatrist might be taken into consideration (61). An overview of a suggested multidimensional approach is summarized in Figure 1.
Figure 1
Life Style Modification
Because smoking and obesity have the greatest association with the severity of the disease, it is recommended that patients with HS stop smoking and reduce their body weight. In addition, loose-fitting clothing in order is advised to avoid friction and mechanical stress (, , ). Zinc might be suggested for patients with Hurley stage I-II, as an innate immunity modulator (, 62).
Pain Management
Acute and chronic pain is a remarkable contributor to quality of life in individuals with HS, and reduction of inflammation can improve the pain (, 63). Depression, which plays a crucial role in the perception of pain, is a risk factor for the development of chronic pain in these patients (, , 63). Managing HS pain is complicated. Therefore, a multidisciplinary approach, including pain assessment, pain scoring, and the involvement of a pain specialist, is warranted (, ). A variety of alternatives are reported in the recent studies, such as local analgesics, non-steroidal paracetamol, anti-inflammatory drugs, pregabalin, gabapentin, venlafaxine, and duloxetine (). In more complex cases may require the judicious use of antidepressants (64). In selected patients with severe pain, careful administration of individualized, short-acting opioid analgesics might be necessary (, ).
Local Therapy and Wound Care
Local treatment of this chronic disorder includes antiseptic washes, keratolytic agents and topical antibiotics (, 60). Selection of dressing is based on the location, skin condition, amount of drainage, cost and patient preference (, 60). For local treatment of selected large open wounds, use of negative-pressure therapy for a short period of time (1–4 weeks) followed by delayed reconstruction might be effective (). Clinical experience supported the use of Intralesional corticosteroid injection (e.g., triamcinolone 3–5 mg) only for short-term control of acute and recalcitrant HS lesions (60, 65). Pain is typically reduced fast and a reduction in edema, erythema, suppuration and lesion size occur after a few days. However, the long-term efficacy of this approach remains unclear and local side effects, most notably skin atrophy, have to be carefully monitored (, 65).
Antibiotics
Available evidence-based literature on the administration of antibiotics in this disorder is limited and mostly restricted to retrospective studies (66). Determining the frequency and duration of antibiotic use should balance of antibiotic use vs. potential harms associated with antibiotic resistance, because findings of recent studies stated that antibiotic therapy for HS treatment might be inducing antibiotic resistance (67). Typically, HS recurs following cessation of antibiotic therapy, making repeated or long-term treatments necessary, with all their potential harmful side effects (60). For Hurley stage I-II, especially in the absence of abscesses, topical clindamycin 1% is a possible therapy (60, 66, 68, 69). However, it carries a high risk of bacterial resistance (60, 66, 68, 69). If there are frequent exacerbations and/or several lesions the administration of systemic antibiotics can be recommended (66, 69). For example, tetracyclines (e.g., doxycycline 50–100 twice daily) are considered in mild-to-moderate HS for a 12-weeks course or as a long-term maintenance alternative, when appropriate (60). For the patients with Hurley stage II-III systemic clindamycin and rifampicin (300 mg twice daily) could be suggested as a second-line therapy for mild-to-moderate HS or as a first-line or adjunct therapy in the patients with severe disease (60, 66, 70, 71). A triple regimen of moxifloxacin (400 mg once daily), rifampicin (10 mg/kg once daily) and metronidazole (500 mg thrice daily) administered for up to 12 weeks, with metronidazole discontinuation after 6 weeks, might be considered as second- or third-line alternative therapy in moderate-to-severe disease (60, 66). Dapsone might be recommended as an effective and safe alternative therapeutic option for a minority of patients as long-term maintenance therapy (60, 72, 73). The effect could be due to either its anti-inflammatory or antibacterial effects, or both. However, rapid recurrence after stopping the therapy suggests that its anti-inflammatory effects are possible more prominent (60, 72).
Other Systemic Therapies
A short-term systemic corticosteroid therapy could be recommended for acute conditions or to bridge to other treatments (60). However, long-term systemic steroid therapy tapered to the lowest possible dose might be an alternative option for the patients with severe disease, as an adjunct therapy in patients without sufficient response to standard recommended therapies (60). Hormonal agents, such as estrogen-containing combined oral contraceptives cyproterone acetate, spironolactone, metformin, and finasteride, might be recommended in the female patients, either as monotherapy for mild-to-moderate disease or in combination with other treatments for severe HS (60, 74–77). Isotretinoin could be recommended only as a second- or third-line treatment or in patients with concomitant acne (60, 78, 79). Cyclosporine might be considered in cases of moderate-to-severe disease who have failed or are not suitable for other therapies (60, 80). Recent studies do not recommend the administration of azathioprine or methotrexate in the treatment of HS (60, 81, 82).
Administration of Biologics in HS
Immunomodulation is becoming popular for moderate-to-severe form of the disease. Targeting the tumor necrosis factor (TNF), interleukin 1 (IL-1), IL-12, and IL-23 has been considered as potential therapies (60, 83).
Adalimumab is recommended as the first-line biologic therapy for moderate-to-severe HS (60, 66), followed by Infliximab and anakinra as second- and third-line options, respectively (66, 84, 85). The recommended dose of adalimumab in HS is 160 mg on Week 0, 80 mg on Week 2 and then 40 mg weekly (60, 66). Recent studies suggest that those patients who do not respond to therapy within 12 weeks (<25% improvement in inflammatory nodules and abscesses) should discontinue the drug (66, 86–89). However, the patients with partial or good should continue the therapy with ongoing assessment (66, 86–89).
Evidence is lacking for other biologic therapies, and any clinical decisions should be based on close monitoring and risk: benefit assessments (66). Recent studies showed administration of other biologics such as other TNF-alpha blockers (66, 90–92), ustekinumab, (93–96) secukinumab, (97, 98) bimekizumab, (99) canakinumab, (, 100) apremilast, (, 101) anakinra, (102) guselkumab (103, 104), and rituximab (105) in management of HS.
Most biologics are well-tolerated and show a favorable safety profile in the short- to medium-term. However, long-term safety concerns, including infection risks, the development of malignancy and demyelinating disorders should be to assessed (). These issues are remarkable in the treatment of HS, where the biologics dosing is generally higher in comparison to other inflammatory skin disorders such as psoriasis. As a result, patient selection is crucial, because complete response is not the norm and not all patients tolerate or respond well to these therapies. Critical monitoring of therapy effects and side effects has to be carefully done under treatment to inform continuous risk-benefit assessment. In case of unfavorable outcome of such assessment, other treatment modalities have to be taken into consideration, such as surgery ().
Surgical Modalities
Planning of type of surgery and required margins should be cleared in cooperation with the patient and based on the severity of the disease (, , 66). Local excision of single lesions is only suggested in well-circumscribed, localized cases of Hurley I-II (). For painful abscesses, no medical therapy will be effective (, , , 66, 106, 107). Therefore, surgical drainage might be demanded to relieve pain; however, this should not be considered as sole treatment, because recurrence is most of the patients inevitable (, , , 66, 106, 107). Extensive excision, electrosurgical excision (with or without reconstruction) CO2 laser could be appropriate for chronic lesions to prevent recurrence (, , 66, 108–111). Wound healing following surgery may be through primary closure, delayed primary closure, secondary intention, grafts, flaps, and/or skin substitutes (, , 66, 108–111). Furthermore, a new surgical approach was described recently, the step-by-step surgery, which consists in consecutively removing portions of HS skin with secondary intention healing (112). Recent studies suggest that continuing medical therapy in the perioperative period might be beneficial and reduce risk of postoperative complications ().
Laser Therapy
Most of laser therapies have been focused of modification of disease activity in the groin and axillae, because, the destruction of the pilosebaceous apparatus might prevent the extension of disease (). Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser is applicable for Hurley stage II-III disease (, , ). Furthermore, CO2 laser excision can be considered in patients with Hurley stage II-III with fibrotic sinus tracts ().
Conclusions
In conclusion, HS is characterized by a pathological reaction pattern of the follicular epithelium of the apocrine gland-bearing skin to yet ill-defined insults. As a result, the follicular epithelium becomes hyperplastic, showing hyperkeratosis of the infundibulum, follicular occlusion, and cyst formation. Rupture of such cysts and consecutive invasion of follicular material into the dermis is likely a key step in triggering a remarkable immune response, which lies at the heart of painful inflammation and abscess formation. In later stages, uncontrolled inflammation leads to sinus tract formation and scarring. There is no uniformly effective therapy for HS. As a result, clinicians should take a multifaceted approach depending on the patients' needs and on features of the disease. Therapy modalities range from self-management and topical treatments to systemic antibiotics, immunomodulating agents, as well as surgical interventions. All in all, it is recommended to avoid the trigger factors such as: smoking, obesity, mechanical friction and shaving. Furthermore, local disinfectants and/or topical antibiotics are suggested in order avoid bacterial superinfections and reduce inflammation. If topical agents are not sufficient, systemic antibiotics are typically given. If antibiotics are not sufficient or no longer effective, other systemic therapies (e.g., adalimumab, dapsone, systemic steroids, or cyclosporine) might be used in patients with refractory disease. Additionally, if needed different surgical interventions might be taken into consideration in cooperation with the patient and based on the severity of the disease.
Statements
Author contributions
SS, RH, and CS designed the study and performed acquisition, analysis, interpretation of data, and wrote the manuscript, and performed critical revision of the manuscript for important intellectual content.
Funding
This study was supported by the Peter Hans Hofschneider Professorship for Molecular Medicine (to CS).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
WeberPSeyed JafariSMYawalkarNHungerRE. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J Am Acad Dermatol. (2017) 76:1189–91. 10.1016/j.jaad.2017.02.026
2.
Seyed JafariSMKnuselECazzanigaSHungerRE. A retrospective cohort study on patients with hidradenitis suppurativa. Dermatology. (2018) 234:71–8. 10.1159/000488344
3.
HourietCSeyed JafariSMThomiRSchlapbachCBorradoriLYawalkarNet al. Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases. JAMA Dermatol. (2017) 153:1195–7. 10.1001/jamadermatol.2017.2392
4.
DeckersIEvan der ZeeHHPrensEP. Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. J Eur Acad Dermatol Venereol. (2016) 30:174–5. 10.1111/jdv.12680
5.
JemecGBHeidenheimMNielsenNH. Hidradenitis suppurativa–characteristics and consequences. Clin Exp Dermatol. (1996) 21:419–23. 10.1111/j.1365-2230.1996.tb00145.x
6.
AlikhanASayedCAlaviAAlhusayenRBrassardABurkhartCet al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. (2019) 81:76–90. 10.1016/j.jaad.2019.02.067
7.
GargAKirbyJSLavianJLinGStrunkA. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. J JAMA Dermatol. (2017) 153:760–4. 10.1001/jamadermatol.2017.0201
8.
IngramJRJenkins-JonesSKnipeDWMorganCLICannings-JohnRPiguetV. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. (2018)178:917–24. 10.1111/bjd.16101
9.
AlikhanALynchPJEisenDB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. (2009) 60:539–61:562–3. 10.1016/j.jaad.2008.11.911
10.
GargALavianJLinGStrunkAAllooA. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. (2017) 77:118–22. 10.1016/j.jaad.2017.02.005
11.
KourisAPlatsidakiEChristodoulouCEfstathiouVDessiniotiCTzanetakouVet al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. (2016) 232:687–91. 10.1159/000453355
12.
WolkensteinPLoundouABarrauKAuquierPRevuzJ. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. (2007) 56:621–3. 10.1016/j.jaad.2006.08.061
13.
EgebergAGislasonGHHansenPR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. (2016) 152:429–34. 10.1001/jamadermatol.2015.6264
14.
ThorlaciusLCohenADGislasonGHJemecGBEEgebergA. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. (2018) 138:52–7. 10.1016/j.jid.2017.09.008
15.
HungerRELaffitteELauchliSMainettiCMuhlstadtMSchillerPet al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology. (2017) 233:113–9. 10.1159/000477459
16.
PrensEDeckersI. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. (2015) 73:S8–11. 10.1016/j.jaad.2015.07.045
17.
VekicDACainsGD. Hidradenitis suppurativa—Management, comorbidities, and monitoring. Aust Fam Physician. (2017) 46:584–8.
18.
von LaffertMStadieVWohlrabJMarschWC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. (2011) 164:367–71. 10.1111/j.1365-2133.2010.10034.x
19.
LimSYDOonHH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. (2019) 13:53–78. 10.2147/BTT.S199862.eCollection2019
20.
NapolitanoMMegnaMTimoshchukEAPatrunoCBalatoNFabbrociniGet al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. (2017) 10:105–15. 10.2147/CCID.S111019.eCollection2017
21.
Canoui-PoitrineFLe ThuautARevuzJEVialletteCGabisonGPoliFet al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. (2013) 133:1506–11. 10.1038/jid.2012.472
22.
IngramJR. The genetics of hidradenitis suppurativa. Dermatol Clin. (2016) 34:23–8. 10.1016/j.det.2015.07.002
23.
PinkAESimpsonMADesaiNTrembathRCBarkerJNW. γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol. (2013) 133:601–7. 10.1038/jid.2012.372
24.
PinkAESimpsonMADesaiNDafouDHillsAMortimerPet al. Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. (2012) 132:2459–61. 10.1038/jid.2012.162
25.
WangBYangWWenWSunJSuBLiuBet al. Gamma-secretase gene mutations in familial acne inversa. Science. (2010) 330:1065. 10.1126/science.1196284
26.
LiAPengYTaicletLMTanziRE. Analysis of hidradenitis suppurativa–linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages. Hum Mol Genet. (2019) 28:1173–82. 10.1093/hmg/ddy414
27.
FrewJWHawkesJEKruegerJG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res. (2018) 7:1930. 10.12688/f1000research.17267.1
28.
ThomiRCazzanigaSSeyed JafariSMSchlapbachCHungerRE. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes. JAMA Dermatol. (2018) 154:592–5. 10.1001/jamadermatol.2018.0141
29.
ThomiRSchlapbachCYawalkarNSimonDYerlyDHungerRE. Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. Exp Dermatol. (2018) 27:172–7. 10.1111/exd.13482
30.
SchlapbachCHanniTYawalkarNHungerRE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. (2011) 65:790–8. 10.1016/j.jaad.2010.07.010
31.
SaunteDMLJemecGBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. (2017) 318:2019–32. 10.1001/jama.2017.16691
32.
HotzCBoniottoMGuguinASurenaudMJean-LouisFTisserandPet al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. (2016) 136:1768–80. 10.1016/j.jid.2016.04.036
33.
van der ZeeHHde RuiterLvan den BroeckeDGDikWALamanJDPrensEP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. (2011) 164:1292–8. 10.1111/j.1365-2133.2011.10254.x
34.
KellyGHughesRMcGarryTvan den BornMAdamzikKFitzgeraldRet al. Dysregulated cytokine expression in lesional and non-lesional skin in hidradenitis suppurativa. Br J Dermatol. (2015) 173:1431–9. 10.1111/bjd.14075
35.
ByrdASCarmona-RiveraCO'NeilLJCarlucciPMCisarCRosenbergAZet al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci Transl Med. (2019) 11:5908. 10.1126/scitranslmed.aav5908
36.
ShanmugamVKJonesDMcNishSBendallMLCrandallKA. Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis. Clin Exp Dermatol. (2019) 44:882–92. 10.1111/ced.13959
37.
RingHCRiis MikkelsenPMillerIMJenssenHFuurstedKSaunteDMet al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp Dermatol. (2015) 24:727–31. 10.1111/exd.12793
38.
VinkelCThomsenSF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol. (2018) 11:17–23
39.
ZouboulisCCDesaiNEmtestamLHungerREIoannidesDJuhaszIet al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. (2015) 29:619–44. 10.1111/jdv.12966
40.
NaikHBNassifARameshMSSchultzGPiguetVAlaviAet al. Are bacteria infectious pathogens in hidradenitis suppurativa? debate at the symposium for hidradenitis suppurativa advances meeting, November 2017. J Invest Dermatol. (2019) 139:13–16. 10.1016/j.jid.2018.09.036
41.
RingHCThorsenJSaunteDMLiljeBBayLRiisPTet al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. (2017) 153:897–905. 10.1001/jamadermatol.2017.0904
42.
RingHCBayLKallenbachKMillerIMPrensESaunteDMet al. Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa. Acta Derm Venereol. (2017) 97:208–13. 10.2340/00015555-2503
43.
RevuzJ. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. (2009) 23:985–98. 10.1111/j.1468-3083.2009.03356.x
44.
Kjaersgaard AndersenRRingHCKallenbachKEriksenJOJemecGBE. Bacterial biofilm is associated with higher levels of regulatory T cells in unaffected hidradenitis suppurativa skin. Exp Dermatol. (2019) 28:312–6. 10.1111/exd.13885
45.
BoerJJemecGB. Mechanical stress and the development of pseudo-comedones and tunnels in Hidradenitis suppurativa/Acne inversa. Exp Dermatol. (2016) 25:396–7. 10.1111/exd.12926
46.
DanbyFW. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol. (2015) 73:S52–4. 10.1016/j.jaad.2015.07.042
47.
RiisPTRingHCThemstrupLJemecGB. The role of androgens and estrogens in hidradenitis suppurativa—a systematic review. Acta Dermatovenerol Croat. (2016) 24:239–49.
48.
EsserCRannugAStockingerB. The aryl hydrocarbon receptor in immunity. Trends Immunol. (2009) 30:447–54. 10.1016/j.it.2009.06.005
49.
HanaABookenDHenrichCGratchevAMaas-SzabowskiNGoerdtSet al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci. (2007) 80:2214–20. 10.1016/j.lfs.2007.02.007
50.
NikotaJKShenPMorissetteMCFernandesKRoosAChuDKet al. Cigarette smoke primes the pulmonary environment to IL-1α/CXCR-2-dependent non-typeable Haemophilus influenzae-exacerbated neutrophilia in mice. J Immunol. (2014) 193:3134–45. 10.4049/jimmunol.1302412
51.
QiuFLiangCLLiuHZengYQHouSHuangSet al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down?Oncotarget. (2017) 8:268–84. 10.18632/oncotarget.13613
52.
RichardsJLYapYAMcLeodKHMackayCRMarinoE. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin Transl Immunology. (2016) 5:e82. 10.1038/cti.2016.29.eCollection2016
53.
KothariVGaldoJAMathewsST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res. (2016) 9:27–38. 10.2147/JIR.S86917.eCollection2016
54.
VossenARvan StraalenKRPrensEPvan der ZeeHH. Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study. J Am Acad Dermatol. (2017) 76:155–6. 10.1016/j.jaad.2016.07.024
55.
EichelerWDreherMHoffmannRHappleRAumullerG. Immunohistochemical evidence for differential distribution of 5 alpha-reductase isoenzymes in human skin. T Br J Dermatol. (1995) 133:371–6. 10.1111/j.1365-2133.1995.tb02663.x
56.
GolbariNMPorterMLKimballAB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. (2019) 80:114–9. 10.1016/j.jaad.2018.06.063
57.
HurleyH. Axillary Hyperhidrosis, Apocrine Bromhidrosis, Hidradenitis Suppurativa, and Familial Benign Pemphigus: Surgical Approach. Dermatologic Surgery.New York, NY: Marcel Dekker. (1989) 729–39.
58.
SartoriusKEmtestamLJemecGBLapinsJ. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. (2009) 161:831–9. 10.1111/j.1365-2133.2009.09198.x
59.
KimballABJemecGBYangMKageleiryASignorovitchJEOkunMMet al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. (2014) 171:1434–42. 10.1111/bjd.13270
60.
AlikhanASayedCAlaviAAlhusayenRBrassardABurkhartCet al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. (2019) 81:91–101. 10.1016/j.jaad.2019.02.068
61.
AndersenRKJemecGB. Treatments for hidradenitis suppurativa. Clin Dermatol. (2017) 35:218–24. 10.1016/j.clindermatol.2016.10.018
62.
ZouboulisCCBecharaFGFritzKKurzenHLiakouAIMarschWCet al. S1 guideline for the treatment of hidradenitis suppurativa/acne inversa*(number ICD-10 L73. 2). J Dtsch Dermatol Ges. (2012) 10:S1–31. 10.1111/j.1610-0387.2012.08006.x
63.
PatelZSHoffmanLKBuseDCGrinbergASAfifiLCohenSRet al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. (2017) 21:49. 10.1007/s11916-017-0647-3
64.
JemecGB. Quality of life considerations and pain management in hidradenitis suppurativa. Semin Cutan Med Surg. (2017) 36:75–8. 10.12788/j.sder.2017.016
65.
Garcia-MartinezFJVilarrasa RullESalgado-BoqueteLMartorellAPascualJCHernandez-MartinAet al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treat. (2019) 29:1–5. 10.1080/09546634.2019.1655524
66.
ZouboulisCCBecharaFGDickinson-BlokJLGulliverWHorvathBHughesRet al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization—systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. (2019) 33:19–31. 10.1111/jdv.15233
67.
FischerAHHaskinAOkoyeGA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. (2017) 76:309–13.e2. 10.1016/j.jaad.2016.08.001
68.
ClemmensenOJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. (1983) 22:325–8. 10.1111/j.1365-4362.1983.tb02150.x
69.
JemecGBWendelboeP. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. (1998) 39:971–4. 10.1016/s0190-9622(98)70272-5
70.
BettoliVZauliSBorghiAToniGMinghettiSRicciMet al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. (2014) 28:125–6. 10.1111/jdv.12127
71.
GenerGCanoui-PoitrineFRevuzJEFayeOPoliFGabisonGet al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. (2009) 219:148–54. 10.1159/000228334
72.
YazdanyarSBoerJIngvarssonGSzepietowskiJCJemecGBE. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. (2011) 222:342–6. 10.1159/000329023
73.
KaurMRLewisHM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. (2006) 17:211–3. 10.1080/09546630600830588
74.
VerdoliniRClaytonNSmithAAlwashNMannelloB. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. (2013) 27:1101–8. 10.1111/j.1468-3083.2012.04668.x
75.
LeeAFischerG. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol. (2015) 56:192–6. 10.1111/ajd.12362
76.
MortimerPSDawberRPGalesMAMooreRA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. (1986) 115:263–8. 10.1111/j.1365-2133.1986.tb05740.x
77.
KhandalavalaBNDoMV. Finasteride in hidradenitis suppurativa: a “male” therapy for a predominantly “female” disease. J Clin Aesthet Dermatol. (2016) 9:44–50.
78.
BoerJvan GemertMJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. (1999) 40:73–6. 10.1016/s0190-9622(99)70530-x
79.
DickenCHPowellSTSpearKL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. (1984) 11:500–2. 10.1016/s0190-9622(84)70199-x
80.
AndersonMDZauliSBettoliVBoerJJemecGB. Cyclosporine treatment of severe Hidradenitis suppurativa–A case series. J Dermatolog Treat. (2016) 27:247–50. 10.3109/09546634.2015.1088128.
81.
NazaryMPrensEPBoerJ. Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients. Br J Dermatol. (2016) 174:639–41. 10.1111/bjd.14086
82.
JemecGB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. (2002) 27:528–9. 10.1046/j.1365-2230.2002.11125.x
83.
HoffmanLKGhiasMHLowesMA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. (2017) 36:47–54. 10.12788/j.sder.2017.017
84.
GrantAGonzalezTMontgomeryMOCardenasVKerdelFA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. (2010) 62:205–17. 10.1016/j.jaad.2009.06.050
85.
TzanetakouVKanniTGiatrakouSKatoulisAPapadavidENeteaMGet al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. (2016) 152:52–9. 10.1001/jamadermatol.2015.3903
86.
KimballABKerdelFAdamsDMrowietzUGelfandJMGniadeckiRet al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. (2012) 157:846–55. 10.7326/0003-4819-157-12-201212180-00004
87.
KimballABOkunMMWilliamsDAGottliebABPappKAZouboulisCCet al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. (2016) 375:422–34. 10.1056/NEJMoa1504370
88.
SotiriouEGoussiCLallasAChovardaEApallaZLazaridouEet al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. (2012) 11:S15–20.
89.
ZouboulisCCOkunMMPrensEPGniadeckiRFoleyPALyndeCet al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. (2019) 80:60–9.e2. 10.1016/j.jaad.2018.05.040
90.
AdamsDRYankuraJAFogelbergACAndersonBE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. (2010) 146:501–4. 10.1001/archdermatol.2010.72
91.
Giamarellos-BourboulisEJPelekanouEAntonopoulouAPetropoulouHBaziakaFKaragianniVet al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. (2008) 158:567–72. 10.1111/j.1365-2133.2007.08372.x
92.
TursiA. Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. Dig Liver Dis. (2016) 48:1511–2. 10.1016/j.dld.2016.09.010
93.
BlokJLLiKBrodmerkelCHorvatovichPJonkmanMFHorvathB. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. (2016) 174:839–46. 10.1111/bjd.14338
94.
GulliverWPJemecGBBakerKA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. (2012) 26:911–4. 10.1111/j.1468-3083.2011.04123.x
95.
Santos-PerezMIGarcia-RodicioSDelOlmo-Revuelto MAPozo-RomanT. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. (2014) 105:720–2. 10.1016/j.ad.2013.09.011
96.
SharonVRGarciaMSBagheriSGoodarziHYangCOnoYet al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. (2012) 92:320–1. 10.2340/00015555-1229
97.
ThorlaciusLTheut RiisPJemecGBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. (2018) 179:182–5. 10.1111/bjd.15769
98.
SchuchAFischerTBoehnerABiedermannTVolzT. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17a antibody secukinumab. Acta Derm Venereol. (2018) 98:151–2. 10.2340/00015555-2794
99.
GlattSHelmerEHaierBStrimenopoulouFPriceGVajjahPet al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. (2017) 83:991–1001. 10.1111/bcp.13185
100.
SunNZRoTJollyPSayedCJ. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. (2017) 10:36–8.
101.
VossenAvan DoornMBAvan der ZeeHHPrensEP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. (2019) 80:80–8. 10.1016/j.jaad.2018.06.046
102.
LeslieKSTripathiSVNguyenTVPauliMRosenblumMD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. (2014) 70:243–51. 10.1016/j.jaad.2013.09.044
103.
KovacsMPoddaM. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. (2019) 33:e140–1. 10.1111/jdv.15368
104.
CasseresRGKahnJSHerMJRosmarinD. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. (2019) 81:265–7. 10.1016/j.jaad.2018.12.017
105.
TakahashiKYanagiTKitamuraSHataHImafukuKIwamiDet al. Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection. J Dermatol. (2018) 45:e116–7. 10.1111/1346-8138.14144
106.
AlharbiZKauczokJPalluaN. A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol. (2012) 12:9. 10.1186/1471-5945-12-9
107.
MitchellKMBeckDE. Hidradenitis suppurativa. Surg Clin North Am. (2002) 82:1187–97. 10.1016/s0039-6109(02)00060-9
108.
SladeDEPowellBWMortimerPS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. (2003) 56:451–61. 10.1016/s0007-1226(03)00177-2
109.
DanbyFWHazenPGBoerJ. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol. (2015) 73:S62–5. 10.1016/j.jaad.2015.07.043
110.
KohorstJJBaumCLOtleyCCRoenigkRKSchenckLAPembertonJHet al. Surgical management of hidradenitis suppurativa: outcomes of 590 consecutive patients. Dermatol Surg. (2016) 42:1030–40. 10.1097/DSS.0000000000000806
111.
van der ZeeHHPrensEPBoerJ. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. (2010) 63:475–80. 10.1016/j.jaad.2009.12.018
112.
SuppaMD'HondtVDaxheletMDel MarmolV. Step by step surgery: a new therapeutic proposal for hidradenitis suppurativa. Exp Dermatol. (2019) 28(Suppl.2):5–55. 10.1111/exd.13893
Summary
Keywords
hidradenitis suppurativa, pathomechanism, pathogenesis, therapy, treatment
Citation
Seyed Jafari SM, Hunger RE and Schlapbach C (2020) Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. Front. Med. 7:68. doi: 10.3389/fmed.2020.00068
Received
18 November 2019
Accepted
14 February 2020
Published
04 March 2020
Volume
7 - 2020
Edited by
Hans Christian Ring, Bispebjerg Hospital, Denmark
Reviewed by
Rune Kjærsgaard Andersen, University of Copenhagen, Denmark; Zrinka Bukvic Mokos, University Hospital Centre Zagreb, Croatia
Updates
Copyright
© 2020 Seyed Jafari, Hunger and Schlapbach.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: S. Morteza Seyed Jafari seyedjafarism@yahoo.com
This article was submitted to Dermatology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.